The case for eliminating excessive worry as a requirement for generalized anxiety disorder: a cross-national investigation.

classification diagnosis epidemiology generalized anxiety disorder global mental health worry

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
04 Oct 2024
Historique:
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 4 10 2024
Statut: aheadofprint

Résumé

Around the world, people living in objectively difficult circumstances who experience symptoms of generalized anxiety disorder (GAD) do not qualify for a diagnosis because their worry is not 'excessive' relative to the context. We carried out the first large-scale, cross-national study to explore the implications of removing this excessiveness requirement. Data come from the World Health Organization World Mental Health Survey Initiative. A total of 133 614 adults from 12 surveys in Low- or Middle-Income Countries (LMICs) and 16 surveys in High-Income Countries (HICs) were assessed with the Composite International Diagnostic Interview. Non-excessive worriers meeting all other Removing the excessiveness requirement increases the global lifetime prevalence of GAD from 2.6% to 4.0%, with larger increases in LMICs than HICs. Non-excessive and excessive GAD cases worry about many of the same things, although non-excessive cases worry more about health/welfare of loved ones, and less about personal or non-specific concerns, than excessive cases. Non-excessive cases closely resemble excessive cases in socio-demographic characteristics, family history of GAD, and risk of temporally secondary comorbidity and suicidality. Although non-excessive cases are less severe on average, they report impairment comparable to excessive cases and often seek treatment for GAD symptoms. Individuals with non-excessive worry who meet all other

Sections du résumé

BACKGROUND BACKGROUND
Around the world, people living in objectively difficult circumstances who experience symptoms of generalized anxiety disorder (GAD) do not qualify for a diagnosis because their worry is not 'excessive' relative to the context. We carried out the first large-scale, cross-national study to explore the implications of removing this excessiveness requirement.
METHODS METHODS
Data come from the World Health Organization World Mental Health Survey Initiative. A total of 133 614 adults from 12 surveys in Low- or Middle-Income Countries (LMICs) and 16 surveys in High-Income Countries (HICs) were assessed with the Composite International Diagnostic Interview. Non-excessive worriers meeting all other
RESULTS RESULTS
Removing the excessiveness requirement increases the global lifetime prevalence of GAD from 2.6% to 4.0%, with larger increases in LMICs than HICs. Non-excessive and excessive GAD cases worry about many of the same things, although non-excessive cases worry more about health/welfare of loved ones, and less about personal or non-specific concerns, than excessive cases. Non-excessive cases closely resemble excessive cases in socio-demographic characteristics, family history of GAD, and risk of temporally secondary comorbidity and suicidality. Although non-excessive cases are less severe on average, they report impairment comparable to excessive cases and often seek treatment for GAD symptoms.
CONCLUSIONS CONCLUSIONS
Individuals with non-excessive worry who meet all other

Identifiants

pubmed: 39364896
doi: 10.1017/S003329172400182X
pii: S003329172400182X
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Subventions

Organisme : U.S. Public Health Service
ID : R13-MH066849; R01-MH069864; R01 DA016558
Organisme : U.S. Department of Defense
Organisme : Generalitat de Catalunya
ID : 2017 SGR 452; 2014 SGR 748
Organisme : FIC NIH HHS
ID : FIRCA R03-TW006481
Pays : United States
Organisme : John D. and Catherine T. MacArthur Foundation
Organisme : European Commission
ID : QLG5-1999-01042; SANCO 2004123; EAHC 20081308
Organisme : EEA Grants
Organisme : Eli Lilly and Company
Organisme : Robert Wood Johnson Foundation
ID : 044708
Organisme : Ministerio de Ciencia y Tecnología
ID : SAF 2000-158-CE
Organisme : U.S. Department of Veterans Affairs
Organisme : National Insurance Institute of Israel
Organisme : GlaxoSmithKline
Organisme : Pan American Health Organization
Organisme : Bristol-Myers Squibb
Organisme : Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
Organisme : SAMHSA HHS
Pays : United States
Organisme : Department of Health and Aged Care, Australian Government
Organisme : Pfizer Foundation
Organisme : John W. Alden Trust
Organisme : Fundação Calouste Gulbenkian
Organisme : Ministerio de Salud de la Nación
ID : 2002-17270/13-5
Organisme : Fundação Champalimaud
Organisme : Ortho-McNeil Pharmaceutical
Organisme : Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
ID : INPRFMDIES 4280

Auteurs

Ayelet Meron Ruscio (AM)

Department of Psychology, University of Pennsylvania, Philadelphia, PA, USA.

Madeleine Rassaby (M)

San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, CA, USA.

Murray B Stein (MB)

Department of Psychiatry and School of Public Health, University of California San Diego, La Jolla, CA, USA.
VA San Diego Healthcare System, San Diego, CA, USA.

Dan J Stein (DJ)

Department of Psychiatry & Mental Health and South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, University of Cape Town, South Africa.

Sergio Aguilar-Gaxiola (S)

Center for Reducing Health Disparities, UC Davis Health System, Sacramento, CA, USA.

Ali Al-Hamzawi (A)

College of Medicine, University of Al-Qadisiya, Diwaniya governorate, Iraq.

Jordi Alonso (J)

Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain.
Department of Medicine and Life Sciences, Pompeu Fabra University (UPF), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Lukoye Atwoli (L)

Brain and Mind Institute and Medical College East Africa, the Aga Khan University, Nairobi, Kenya.

Guilherme Borges (G)

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico.

Evelyn J Bromet (EJ)

Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY, USA.

Ronny Bruffaerts (R)

Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium.

Brendan Bunting (B)

School of Psychology, Ulster University, Coleraine, UK.

Graça Cardoso (G)

Lisbon Institute of Global Mental Health and Chronic Diseases Research Center, NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal.

Stephanie Chardoul (S)

Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.

Giovanni de Girolamo (G)

IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Peter de Jonge (P)

Department of Developmental Psychology, University of Groningen, Groningen, The Netherlands.

Oye Gureje (O)

Department of Psychiatry, University College Hospital, Ibadan, Nigeria.

Josep Maria Haro (JM)

Research, Teaching and Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Elie G Karam (EG)

Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon.
Institute for Development, Research, Advocacy and Applied Care (IDRAAC), Beirut, Lebanon.

Aimee Karam (A)

Institute for Development, Research, Advocacy and Applied Care (IDRAAC), Beirut, Lebanon.

Andrzej Kiejna (A)

Faculty of Applied Studies, University of Lower Silesia, Wroclaw, Poland.

Viviane Kovess-Masfety (V)

Institut de Psychologie, EA 4057, Université Paris Cité, Paris, France.

Sue Lee (S)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Fernando Navarro-Mateu (F)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Unidad de Docencia, Investigación y Formación en Salud Mental (UDIF-SM), Gerencia Salud Mental, Servicio Murciano de Salud, Murcia, Spain.

Daisuke Nishi (D)

Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Marina Piazza (M)

School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.

José Posada-Villa (J)

Faculty of Social Sciences, Colegio Mayor de Cundinamarca University, Bogota, Colombia.

Nancy A Sampson (NA)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Kate M Scott (KM)

Department of Psychological Medicine, University of Otago, Dunedin, New Zealand.

Tim Slade (T)

The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Australia.

Juan Carlos Stagnaro (JC)

Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina.

Yolanda Torres (Y)

Center for Excellence on Research in Mental Health, CES University, Medellín, Colombia.

Maria Carmen Viana (MC)

Department of Social Medicine, Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitoria, Brazil.

Cristian Vladescu (C)

National Institute of Health Services Management, Bucharest, Romania.
University Titu Maiorescu, Bucharest, Romania.

Zahari Zarkov (Z)

Department of Mental Health, National Center of Public Health and Analyses, Sofia, Bulgaria.

Ronald C Kessler (RC)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Classifications MeSH